F-star signs deal with AbbVie for bispecific antibodies in immuno-oncology

Biotech company F-star on Monday said it has entered into a collaboration and license agreement with US drugmaker AbbVie (NYSE: ABBV) to research and develop bispecific antibodies in immuno-oncology.

No financial terms were disclosed.

John Haurum, chief executive officer, said: “We are very excited to be working with AbbVie on these immuno-oncology programmes to develop new bispecific antibodies. Bispecific antibodies are expected to be the cornerstone of the next generation of immuno-oncology products and this collaboration validates our technology as truly novel and differentiated in the space.”